BIIB vs AMGN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BIIB · Biogen$248.35 ▲ 1.81%
AMGN · Amgen$460.42 ▲ 0.03%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BIIB +58.9%
- AMGN +46.2%
Head to head
| Metric | BIIB | AMGN |
|---|---|---|
| Price | $248.35 | $460.42 |
| Change today | ▲ 1.81% | ▲ 0.03% |
| Market cap | $36.71B | $249.05B |
| Return, 3 months | +19.9% | +11.0% |
| Return, year to date | +41.1% | +43.5% |
| Return, 1 year | +59.7% | +47.8% |
| P/E (TTM) | 107.5 | 26.7 |
| P/B | 1.9 | 17.4 |
| P/E percentile vs own 5y | 100th | 80th |
| Dividend yield | – | 2.16% |
| Revenue growth (YoY, latest qtr) | +10.6% | +9.5% |
| Net profit growth (YoY) | -104.4% | +65.9% |
| Gross margin | 74.0% | 69.5% |
| Operating margin | 17.6% | 30.0% |
| Net margin | 3.4% | 23.0% |
| Return on equity | 1.9% | 91.5% |
| Analyst target vs. price | +9.1% | +0.5% |
| Analyst buy share | 82% | 47% |
| RSI (14) | 57 | 60 |
| 30-day volatility | 32.6% | 29.0% |
| Max drawdown, 1 year | -14.3% | -16.6% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AMGN is the largest of the group by market value.
- BIIB has returned the most over the past year.
- AMGN carries the lowest trailing P/E.
- BIIB is growing revenue fastest.
- AMGN keeps the most profit per dollar of sales.
- AMGN has been the calmest stock over the last 30 days.